LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC
-
Published:2024-05
Issue:
Volume:Volume 15
Page:75-80
-
ISSN:1179-2728
-
Container-title:Lung Cancer: Targets and Therapy
-
language:en
-
Short-container-title:LCTT
Author:
Lee AlexandriaORCID,
Ou Sai-HongORCID
Publisher
Informa UK Limited